Q-omics provides the consensus-scored RPS17P15 profile across patient tissues and cancer cell-line models. RPS17P15 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPS17P15 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, RPS17P15 RNA expression shows 4,817 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight THCA, and UCEC as cancer lineages where RPS17P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS17P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS17P15 survival associations across molecular data types. RPS17P15 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS17P15 RNA expression–survival associations across cancer types. High RPS17P15 expression shows unfavorable associations in THCA, KIRP, BRCA, STAD, BLCA and ACC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for RPS17P15 RNA expression.
This table summarizes RPS17P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS17P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS17P15 shows lower tumor expression in THCA, KIRC, COAD and LIHC and higher tumor expression in HNSC and LUAD. The THCA box plot shows higher RPS17P15 RNA expression in normal versus tumor tissue (log2 FC = −0.175, t-test p < 0.001).
This table shows molecular features associated with RPS17P15 in patient tissues and cancer cell lines. In patient samples, RPS17P15 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
